{"content":[{"text":"4. CuATSM PET to diagnose age-related diseases: a systematic literature review. Clinical and \n Translational Imaging, 2020. Published online November 2020.","bbox":{"left":0.121,"top":0.129224,"width":0.703995,"height":0.03437899999999999}},{"text":"Majerníková N., Yu J.J., Maier A.B.","bbox":{"left":0.121,"top":0.177941,"width":0.25777,"height":0.01594699999999999}},{"text":"About the Research: Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission \n tomography (CuATSM PET) is a non-invasive imaging technique that can be used to detect hypoxia \n and inform prognosis in cancer. Hypoxia and oxidative stress are also hallmarks of various age- \n related diseases. Whether CuATSM PET has a role in the evaluation of hypoxia and oxidative stress in \n age-related diseases has yet to be established. The aim of this systematic review is to evaluate the \n utility of CuATSM PET in the diagnosis and management of age-related diseases.","bbox":{"left":0.121,"top":0.223962,"width":0.756386,"height":0.10772900000000002}},{"text":"Link to Publication","bbox":{"left":0.121,"top":0.346053,"width":0.13856800000000002,"height":0.01594699999999999}},{"text":"5. Iron and Ferroptosis as Therapeutic Targets in Alzheimer’s Disease. Neurotherapeutics, 2020 \n Published online November 2020.","bbox":{"left":0.121,"top":0.436611,"width":0.7205499999999999,"height":0.03437899999999994}},{"text":"Gleason A., Bush A.I.","bbox":{"left":0.121,"top":0.485328,"width":0.156889,"height":0.015947000000000044}},{"text":"About the Research: Alzheimer’s disease (AD), one of the most common neurodegenerative \n diseases worldwide, has a devastating personal, familial, and societal impact. In spite of profound \n investment and effort, numerous clinical trials targeting amyloid-β, which is thought to have a \n causative role in the disease, have not yielded any clinically meaningful success to date. Iron is an \n essential cofactor in many physiological processes in the brain. An extensive body of work links iron \n dyshomeostasis with multiple aspects of the pathophysiology of AD. In particular, regional iron load \n appears to be a risk factor for more rapid cognitive decline. Existing iron-chelating agents have been \n in use for decades for other indications, and there are preliminary data that some of these could be \n effective in AD. Many novel iron-chelating compounds are under development, some with in vivo \n data showing potential Alzheimer’s disease-modifying properties. This heretofore underexplored \n therapeutic class has considerable promise and could yield much-needed agents that slow \n neurodegeneration in AD.","bbox":{"left":0.121,"top":0.517098,"width":0.751512,"height":0.19148100000000012}},{"text":"Link to publication","bbox":{"left":0.121,"top":0.738962,"width":0.138586,"height":0.015947000000000044}},{"text":"2","bbox":{"left":0.870172,"top":0.926071,"width":0.009365999999999985,"height":0.015947000000000044}}],"images_bbox":[{"left":0.120958,"top":0.042043,"width":0.247341,"height":0.056413},{"left":0.724318,"top":0.047981,"width":0.219236,"height":0.046734}],"images_bbox_not_text_overlap":[{"left":0.120958,"top":0.042043,"width":0.247341,"height":0.056413},{"left":0.724318,"top":0.047981,"width":0.219236,"height":0.046734}]}